Prediabetes: Causes, Symptoms, Diagnosis, and How to Reverse It

What Prediabetes Actually Is

Prediabetes is not early diabetes. It is a distinct physiological state in which the pancreatic beta cells are still compensating for insulin resistance but are beginning to lose ground. Blood glucose climbs above the normal range yet stays below the thresholds that define type 2 diabetes. The American Diabetes Association (ADA) defines prediabetes as a fasting plasma glucose (FPG) of 100-125 mg/dL, a 2-hour plasma glucose of 140-199 mg/dL on a 75 g oral glucose tolerance test (OGTT), or an HbA1c of 5.7%-6.4% [1]. Any one of these three positive values is sufficient for diagnosis on repeat testing.

The condition sits at a biological fork in the road. Beta cells in the pancreas begin secreting excess insulin to compensate for peripheral resistance, a state called hyperinsulinemia. Over time, if resistance worsens and compensation fails, glucose rises into the diabetic range. The CDC estimates that 98 million American adults, about 38% of the U.S. adult population, currently meet criteria for prediabetes, and roughly 80% do not know it [2].

Early detection matters because the window for reversal is wide. Returning fasting glucose below 100 mg/dL or HbA1c below 5.7% substantially reduces the risk of cardiovascular disease, chronic kidney disease, and neuropathy, even before a diabetes diagnosis is ever made [3].

How Insulin Resistance Drives Prediabetes

Insulin is a peptide hormone secreted by pancreatic beta cells in response to rising blood glucose [4]. When you eat carbohydrates, glucose enters the bloodstream and signals the pancreas to release insulin. Insulin binds receptors on skeletal muscle, the liver, and adipose tissue, allowing glucose to move from blood into cells for energy or storage.

Insulin resistance develops when those receptor pathways stop responding normally. Skeletal muscle, which clears roughly 75-80% of a postprandial glucose load, becomes the first site of failure [5]. The liver follows: it continues producing glucose through gluconeogenesis even when blood glucose is already elevated, a process that healthy insulin signaling would suppress. Adipose tissue releases excess free fatty acids, which worsen hepatic and muscle insulin sensitivity in a self-reinforcing cycle.

To compensate, the pancreas releases more insulin. Fasting insulin can rise to two or three times the normal concentration. For a period measured in years to decades, this hyperinsulinemia keeps fasting glucose in the normal range. The OGTT unmasks the problem early because it stresses the system: postprandial glucose climbs higher and takes longer to return to baseline [6]. That is why a 2-hour OGTT often identifies insulin resistance several years before fasting glucose crosses the prediabetes threshold.

Excess visceral adiposity, physical inactivity, chronic sleep deprivation, and certain medications (glucocorticoids, atypical antipsychotics, thiazide diuretics) all worsen insulin sensitivity. Genetic background also contributes. First-degree relatives of people with type 2 diabetes show measurably reduced insulin-stimulated glucose uptake even at normal body weight [7].

Prediabetes Symptoms: Why Most People Have None

Prediabetes rarely causes symptoms. That is a clinical problem, not a reassurance. Most people feel well, which is exactly why 80% of affected adults are unaware of their status [2]. When symptoms do appear, they tend to be subtle: mild fatigue after meals, difficulty losing weight despite caloric restriction, and skin changes such as acanthosis nigricans, a velvety darkening of skin folds at the neck and armpits caused by chronically elevated insulin [8].

Acanthosis nigricans is the most visible physical sign. It appears because insulin, at high concentrations, cross-activates insulin-like growth factor-1 (IGF-1) receptors in keratinocytes, stimulating epidermal proliferation. Its presence strongly predicts underlying insulin resistance and warrants laboratory screening even in younger patients [8].

Some patients describe postprandial energy crashes roughly 90-120 minutes after high-carbohydrate meals. This reactive pattern reflects disordered first-phase insulin secretion: glucose rises steeply, the pancreas overshoots its insulin release, and glucose then drops faster than normal. The feeling is unpleasant but not diagnostic on its own.

Erectile dysfunction in men and irregular menstrual cycles in women with polycystic ovary syndrome (PCOS) may also reflect underlying insulin resistance, as insulin directly modulates gonadal steroid production [9].

Who Should Be Screened and When

The ADA's 2024 Standards of Care recommend screening all adults aged 35 and older, regardless of weight or other risk factors, every 3 years with a normal result [1]. Screening should begin earlier, and happen more frequently, when any of the following are present:

• BMI <27 with at least one additional metabolic risk factor, or BMI 27 or higher without other risk factors
• Physical inactivity
• First-degree relative with type 2 diabetes
• High-risk ethnicity (Black, Hispanic, Native American, Asian American, Pacific Islander ancestry)
• History of gestational diabetes or delivery of an infant weighing more than 9 pounds
• Polycystic ovary syndrome
• Hypertension (blood pressure at or above 140/90 mmHg or on antihypertensive therapy)
• HDL cholesterol below 35 mg/dL or triglycerides above 250 mg/dL
• HbA1c of 5.7%-6.4% on a previous test
• History of cardiovascular disease

Asian Americans warrant attention at lower BMI thresholds. The ADA recommends screening Asian American adults at BMI 23 or higher because visceral fat accumulates at lower total body weights in this population, producing insulin resistance at lighter overall mass [1].

The U.S. Preventive Services Task Force (USPSTF) recommends screening for abnormal blood glucose in adults aged 35-70 who are overweight or have obesity, and referring those with prediabetes to a preventive intervention program [10]. Both the ADA and USPSTF converge on the Diabetes Prevention Program model as the preferred intervention.

Diagnosing Prediabetes: Three Valid Tests

Three laboratory tests can establish the diagnosis. Each has distinct clinical characteristics [1, 11]:

Fasting plasma glucose (FPG). Measured after at least 8 hours without caloric intake. Prediabetes: 100-125 mg/dL. Type 2 diabetes: 126 mg/dL or higher on two separate occasions. FPG is convenient but misses postprandial dysglycemia in some patients.

HbA1c. Reflects average blood glucose over the prior 8-12 weeks by measuring glycation of hemoglobin. Prediabetes: 5.7%-6.4%. Type 2 diabetes: 6.5% or higher. HbA1c does not require fasting and is reproducible across visits, making it practical for primary care. Results may be falsely low in hemolytic anemia or certain hemoglobin variants, and falsely high in iron deficiency [12].

2-hour 75 g OGTT. The most sensitive test for early insulin resistance. The patient drinks 75 g of glucose solution; plasma glucose is measured exactly 2 hours later. Prediabetes: 140-199 mg/dL. Type 2 diabetes: 200 mg/dL or higher. The OGTT is the standard diagnostic tool for gestational diabetes screening, adapted to a 75 g or 100 g load depending on the protocol used [13].

Confirmation on a second test is standard except when a single clearly abnormal result is combined with classic hyperglycemic symptoms.

The Diabetes Prevention Program: What the Data Show

The Diabetes Prevention Program (DPP) remains the most cited trial in prediabetes research. Enrolled 3,234 adults with prediabetes (mean age 51, mean BMI 34) and randomized them to intensive lifestyle intervention, metformin 850 mg twice daily, or placebo. The lifestyle arm targeted 7% weight loss and 150 minutes per week of moderate-intensity physical activity [14].

At an average 2.8 years of follow-up, the lifestyle intervention reduced progression to type 2 diabetes by 58% compared to placebo (P<0.001). Metformin reduced progression by 31% compared to placebo (P<0.001). The lifestyle benefit was greatest in adults aged 60 and older, where risk reduction reached 71% [14]. The DPP Outcomes Study (DPPOS), which followed participants for an additional 15 years, confirmed that lifestyle benefits persisted: cumulative diabetes incidence remained lower in the lifestyle arm than placebo even a decade after the intensive intervention ended [15].

These numbers mean a 58% risk reduction is achievable without any prescription medication. For many patients, that is the most motivating statistic in the entire field.

How Much Weight Loss Is Needed

Body weight and insulin resistance are tightly linked, but the relationship is not linear. Losing 5-7% of body weight reliably improves insulin sensitivity in muscle and liver, reduces fasting glucose, and often brings HbA1c back below the prediabetes threshold [14]. For a 220-pound adult, that is 11-15 pounds.

The mechanism involves both reduced visceral adiposity and direct metabolic signaling. Each kilogram of weight lost in overweight adults is associated with approximately a 0.1% reduction in HbA1c, based on pooled analyses of lifestyle intervention trials [16]. Losing more than 10% of body weight produces greater effects, and some patients achieve complete normalization of glucose tolerance.

Caloric composition matters less than caloric deficit and sustainability. Low-carbohydrate, Mediterranean, and low-glycemic-index dietary patterns all reduce postprandial glucose excursions and have each shown benefit in randomized controlled trials [17]. The pattern a patient will actually maintain over years is, by definition, the best pattern for that patient.

Exercise as a Direct Insulin-Sensitizing Intervention

Physical activity improves insulin sensitivity through a mechanism that bypasses the defective insulin receptor pathway entirely. Muscle contraction activates GLUT4 transporter translocation to the cell surface via AMP-activated protein kinase (AMPK), allowing glucose uptake even when insulin signaling is blunted [18]. This effect begins within the first session and persists for 24-72 hours after exercise.

The DPP prescribed 150 minutes per week of moderate-intensity aerobic activity, the equivalent of five 30-minute brisk walks. That dose alone accounted for a meaningful share of the lifestyle arm's benefit independent of weight loss [14]. Adding resistance training amplifies the effect further. A 2012 trial published in the Annals of Internal Medicine (N=262) found that combined aerobic and resistance training reduced HbA1c by 0.34 percentage points more than either modality alone in adults with type 2 diabetes, a magnitude relevant to prediabetes management [19].

Sedentary time, separate from exercise, also predicts insulin resistance. Breaking up prolonged sitting with 2-3 minutes of light activity every 30 minutes reduces postprandial glucose by approximately 17% compared to uninterrupted sitting, according to data from a randomized crossover study [20].

Medications Used in Prediabetes

Lifestyle intervention is the first choice. Pharmacotherapy is an option when lifestyle changes alone fail to prevent progression, when risk is very high (HbA1c close to 6.4%, history of gestational diabetes, severe obesity), or when patients cannot sustain the required behavioral changes [1].

Metformin is the only medication the ADA endorses for prediabetes outside of clinical trials. The DPP demonstrated 31% risk reduction at a dose of 850 mg twice daily [14]. Metformin works primarily by suppressing hepatic glucose production and may modestly improve peripheral insulin sensitivity. Common side effects are gastrointestinal: nausea, diarrhea, and bloating, which can be minimized by starting at 500 mg once daily with the evening meal and titrating slowly. Long-term metformin use depletes vitamin B12; monitoring annually is appropriate [1].

GLP-1 receptor agonists such as semaglutide produce substantial weight loss (up to 14.9% at 68 weeks in STEP-1, N=1,961) and markedly improve insulin sensitivity, but are not currently FDA-approved for prediabetes as a labeled indication [21]. Clinicians prescribe them off-label when obesity with prediabetes warrants pharmacologic weight management.

Thiazolidinediones (pioglitazone) reduced progression to diabetes by 72% in the ACT NOW trial (N=602), but weight gain and bone fracture risk limit routine use [22].

No medication substitutes for the 58% risk reduction achievable through lifestyle change alone.

Prediabetes in Special Populations

Gestational Diabetes

Gestational diabetes mellitus (GDM) affects approximately 6-9% of pregnancies in the United States [23]. GDM represents a stress test of beta-cell reserve: the placenta secretes hormones (human placental lactogen, progesterone, cortisol) that reduce insulin sensitivity. Women whose beta cells cannot compensate develop GDM. After delivery, glucose typically normalizes, but GDM is a powerful predictor of future prediabetes and type 2 diabetes. Women with a history of GDM carry a 7-fold greater lifetime risk of developing type 2 diabetes compared to women with glucose-tolerant pregnancies [24]. ADA guidelines recommend screening for prediabetes at 4-12 weeks postpartum with a 75 g OGTT, and rescreening every 1-3 years thereafter [1].

Type 1 Diabetes and the Prediabetes Distinction

Type 1 diabetes involves autoimmune destruction of pancreatic beta cells and is a separate disease from the insulin-resistance-driven progression described above. Prediabetes as a category refers specifically to the pathway leading to type 2 diabetes. However, individuals with type 1 diabetes can also develop insulin resistance over time, a phenomenon called "double diabetes" or type 3c features, especially with weight gain or steroid use. The management of insulin resistance in type 1 diabetes may include metformin or GLP-1 receptor agonists as adjuncts to insulin therapy [25].

Menopause and Estrogen Decline

Estrogen directly modulates insulin sensitivity by upregulating insulin receptor expression in skeletal muscle and suppressing hepatic glucose production. As estrogen falls during perimenopause, insulin sensitivity measurably declines. A 2021 analysis in Menopause (the journal of the Menopause Society) found that postmenopausal women had significantly higher HOMA-IR scores, a validated surrogate for insulin resistance, compared to premenopausal controls after adjusting for age and BMI [26]. Women transitioning through menopause who already carry prediabetes risk factors warrant increased screening frequency and proactive lifestyle counseling.

Prediabetes Reversal: What It Means and Whether It Lasts

Reversal is defined as returning HbA1c to below 5.7% or fasting glucose to below 100 mg/dL on repeat testing without ongoing pharmacotherapy. It is achievable. An analysis of DPP participants found that 38% of those in the lifestyle arm returned to normal glucose regulation at 1 year [14]. The DiRECT trial (N=298), which studied an intensive dietary intervention in adults with established type 2 diabetes, found that 46% achieved remission at 1 year and 36% maintained remission at 2 years, illustrating that even frank diabetes can be reversed with sufficient weight loss [27].

Reversal is not permanent if the behaviors that produced it are discontinued. Beta-cell function, though improved, remains vulnerable. Patients who normalize their glucose should continue annual HbA1c monitoring indefinitely. The goal is not a single clean test result but sustained metabolic health over decades.

Practical Next Steps for Patients Diagnosed With Prediabetes

A prediabetes diagnosis is best treated as a specific, time-sensitive clinical signal rather than a vague warning. The following steps are grounded in ADA 2024 Standards of Care [1]:

1. Confirm the diagnosis with a second test if only one value was obtained.
2. Enroll in a CDC-recognized Diabetes Prevention Program (DPP) lifestyle intervention. These are available in-person and digitally; the YMCA's DPP is one widely accessible option covered by Medicare.
3. Target 7% body weight reduction. For most patients this requires a sustained caloric deficit of approximately 500-750 kcal/day.
4. Achieve at least 150 minutes per week of moderate-intensity aerobic activity, distributed across at least 3 days, with no more than 2 consecutive days without activity.
5. Discuss metformin with your clinician if your HbA1c is 6.0%-6.4%, if you have a history of gestational diabetes, or if lifestyle intervention alone has not produced measurable improvement after 3-6 months.
6. Recheck HbA1c or fasting glucose at 3-6 months to assess response, then annually if normalized.

The ADA states: "Lifestyle intervention is the most effective approach for preventing type 2 diabetes in those with prediabetes" [1].